TG6050
Non-small Cell Lung Cancer (NSCLC)
PreclinicalIND-enabling
Key Facts
About Transgene SA
Transgene SA is a clinical-stage biotech company developing a new generation of immunotherapies to treat cancer. Its core expertise lies in engineering viral vectors, including Vaccinia and Adenovirus platforms, to stimulate the patient's immune system against tumors. The company has built a diversified pipeline of oncolytic viruses and therapeutic vaccines, primarily in Phase 1 and 2 trials, and maintains strategic collaborations with major players like Institut Mérieux and NEC Corporation. Its strategy is to advance its lead candidates while expanding its technology's application through partnerships.
View full company profileTherapeutic Areas
Other Non-small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| NBTXR3 + anti-PD1 | Nanobiotix | Phase 1 |
| TTFields | Novocure | Phase 3 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1/2 |
| VAC2 | Lineage Cell Therapeutics | Phase 1 |
| Monalizumab (IPH2201) | Innate Pharma | Phase 3 |
| Plinabulin | BeyondSpring | Phase 2/3 |
| PD1-Vaxx (IMU-201) | Imugene | Phase 1 |
| ATNM-400 | Actinium Pharmaceuticals | Preclinical |
| Reqorsa® (quaratusugene ozeplasmid) + Keytruda® (pembrolizumab) | Genprex | Phase 1/2 |
| ABD-3001 | Advanced Biodesign | Phase 1 |